In adults with obesity or overweight with 1 weight-related comorbidity, along with diet and exercise, A well-studied safety profile: Pooled safety data from 3 weight-management clinical trials evaluating Wegovy 2.4 mg pen 1 6.8% of patients treated with Wegovy and 3.2% of patients treated with placebo permanently discontinued treatment as a result of adverse reactions 1 Permanent discontinuation of treatment as a result of a gastrointestinal adverse reaction occurred in 4.3% of patients treated with Wegovy vs 0.7% of patients treated with placebo 1 The most common adverse reactions leading to discontinuation were: Nausea (1.8% vs 0.2%) , vomiting (1.2% vs 0%) , and diarrhea (0.7% vs 0.1%) for Wegovy and placebo, respectively 2 *Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort, and epigastric discomfort

This makes semaglutide particularly effective for patients whose weight gain stems from hormonal disruption rather than behavioral factors alone
Glentham Life Sciences products is very good quality and quickly response him You science and research partner
Accordingly, our data reflect actual population-based clinical practice in diabetes care
FDA-Approved Injectable Wegovy Pricing Based on Novo Nordisk's November 2025 pricing update, injectable Wegovy offers reduced pricing for uninsured patients during the initial dosing phase